The company, formerly a state-owned enterprise of Hangzhou cement products factory, was restructured into a private enterprise in 2000. In 2004, the group was established and transformed into a health industry, with a total of more than 80 employees (including 15 with middle and senior titles). At present, it has two parts, i.e. bio medicine Hangzhou Tianlong Pharmaceutical Co., Ltd. with a registered capital of 10 million yuan, and health food Zhejiang Golden Flax Industry Co., Ltd. with a registered capital of 100 million yuan (over 20 million yuan paid in), which is a comprehensive enterprise integrating high-end R & D, production and sales.
In 2009, it cooperated with the Academy of military medicine of the Academy of Military Sciences in the research of innovative nucleic acid drugs. It has the National Center for nucleic acid drug research and engineering, and its academic committee is composed of three academicians. The project has been listed as one of the four national R & D centers in strategic cooperation between Zhejiang provincial government and Military Medical Research Institute, and has become one of the civil military integration projects. At present, the company is researching six new nucleic acid candidate varieties, involving the prevention and treatment of major diseases such as cancer, influenza, hepatitis B, hand foot mouth disease, etc., three new nucleic acid class I drugs have basically completed the preclinical research content, among which the anti-tumor class I new drug "ct102" has obtained the clinical approval of the State Food and drug administration, realizing the first antisense oligonucleic acid drug entering the clinical stage in China. At present, the company has presided over and participated in 8 national level projects such as national 863 project and "major new drug creation", applied for more than 20 related invention patents in the field of nucleic acid, and now negotiated with the two companies to enter the first phase of clinical application of anticancer drug ct102.In 2012, we entered the flax health industry, specialized in the research and development of plant water-soluble human essential nutrients omega-3 elements, created the "Golden Flax" brand, and has three series of 19 products. At present, we have established cooperative relations with Military Medical Research Institute, Zhejiang University, Cambridge University, etc., established the Flax Industry Research Institute, and applied for invention patents in the field of flaxseed In 2016, three professional monographs were published, and the water-soluble omega-3 series of innovative products represented by instant flax powder and flax milk began to be developed and put on the market. Golden Flax signed an agreement with Huining county government of Gansu Province, the hometown of flax seeds in China, to provide guarantee for the supply of green raw materials. In the same year, the first phase of the production base was built in Qiandao Lake, Hangzhou It has passed ISO22000 and HACCP certification and was rated as a national high-tech enterprise in 2019.In 2020, "Golden Flax" officially launched the listing work, striving to complete the listing target of Hong Kong main board within three years. In order to meet the market demand, "Golden Flax" plans to build a multi-functional modern flaxseed Culture Industrial Park in Qiandao Lake High Speed Railway New Area, which integrates product research and production, tourism, factory demonstration, health science popularization and flax culture exhibition "Golden Flax" brand publicity window, build the whole industry chain of flax health, drive the targeted poverty alleviation in Northwest China through industrial development, pass the flax health concept and products to the world, build a "hundred year enterprise, 10 billion output value, 100 year life", and develop into the leader of the global flax industry.
